The role of enhancing capsule and modified capsule appearances in LI-RADS for diagnosing HCC ≤ 3.0 cm on gadoxetate disodium–enhanced MRI

[1] Heimbach JK(2018)AASLD guidelines for the treatment of hepatocellular carcinoma Hepatology 67 358-380

[2] Kulik LM(2017)Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update Hepatol Int 11 317-370

[3] Finn RS(2018)Liver Imaging Reporting and Data System (LI-RADS) Version 2018: imaging of hepatocellular carcinoma in at-risk patients Radiology 289 816-830

[4] Omata M(2022)A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions Eur Radiol 32 912-922

[5] Cheng AL(2021)LI-RADS Major features on MRI for diagnosing hepatocellular carcinoma: a systematic review and meta-analysis J Magn Reson Imaging 54 518-525

[6] Kokudo N(2018)LI-RADS for MR imaging diagnosis of hepatocellular carcinoma: performance of major and ancillary features Radiology 288 118-128

[7] Chernyak V(2015)MRI features of hepatocellular carcinoma related to biologic behavior Korean J Radiol 16 449-464

[8] Fowler KJ(2021)Inter-reader reliability of CT Liver Imaging Reporting and Data System according to imaging analysis methodology: a systematic review and meta-analysis Eur Radiol 31 6856-6867

[9] Kamaya A(2022)Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system vol 2018 and European association for the study of the liver criteria Hepatology 214 72-80

[10] Min JH(2020)Subtraction images from portal venous phase gadoxetic acid-enhanced MRI for observing washout and enhancing capsule features in LI-RADS version 2018 AJR Am J Roentgenol 44 3078-3088

[1] Heimbach JK(2018)AASLD guidelines for the treatment of hepatocellular carcinoma Hepatology 67 358-380

[2] Kulik LM(2017)Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update Hepatol Int 11 317-370

[3] Finn RS(2018)Liver Imaging Reporting and Data System (LI-RADS) Version 2018: imaging of hepatocellular carcinoma in at-risk patients Radiology 289 816-830

[4] Omata M(2022)A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions Eur Radiol 32 912-922

[5] Cheng AL(2021)LI-RADS Major features on MRI for diagnosing hepatocellular carcinoma: a systematic review and meta-analysis J Magn Reson Imaging 54 518-525

[6] Kokudo N(2018)LI-RADS for MR imaging diagnosis of hepatocellular carcinoma: performance of major and ancillary features Radiology 288 118-128

[7] Chernyak V(2015)MRI features of hepatocellular carcinoma related to biologic behavior Korean J Radiol 16 449-464

[8] Fowler KJ(2021)Inter-reader reliability of CT Liver Imaging Reporting and Data System according to imaging analysis methodology: a systematic review and meta-analysis Eur Radiol 31 6856-6867

[9] Kamaya A(2022)Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system vol 2018 and European association for the study of the liver criteria Hepatology 214 72-80

[10] Min JH(2020)Subtraction images from portal venous phase gadoxetic acid-enhanced MRI for observing washout and enhancing capsule features in LI-RADS version 2018 AJR Am J Roentgenol 44 3078-3088